

# Gary R Matzke

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11359400/gary-r-matzke-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74  
papers

2,407  
citations

26  
h-index

48  
g-index

79  
ext. papers

2,665  
ext. citations

3.9  
avg, IF

4.32  
L-index

#	Paper	IF	Citations
74	Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. <i>Clinical Pharmacology and Therapeutics</i> , <b>1997</b> , 62, 365-76	6.1	206
73	Liver disease selectively modulates cytochrome P450-mediated metabolism. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 235-45	6.1	171
72	Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , <b>1996</b> , 27, 162-5	7.4	155
71	Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i> , <b>2009</b> , 29, 562-77	5.8	123
70	Validity of creatinine clearance estimates in the assessment of renal function. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 48, 503-8	6.1	104
69	Pharmacokinetics of cefepime in subjects with renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 48, 268-76	6.1	103
68	Hepatic drug metabolism and transport in patients with kidney disease. <i>American Journal of Kidney Diseases</i> , <b>2003</b> , 42, 906-25	7.4	89
67	A primer on continuous renal replacement therapy for critically ill patients. <i>Annals of Pharmacotherapy</i> , <b>1998</b> , 32, 362-75	2.9	81
66	Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. <i>Clinical Pharmacology and Therapeutics</i> , <b>1988</b> , 43, 63-71	6.1	72
65	Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. <i>Drug Safety</i> , <b>1997</b> , 16, 205-31	5.1	68
64	Controlled comparison of gentamicin and tobramycin nephrotoxicity. <i>American Journal of Nephrology</i> , <b>1983</b> , 3, 11-7	4.6	66
63	Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. <i>Pharmacotherapy</i> , <b>2000</b> , 20, 182-90	5.8	53
62	Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. <i>Pharmacotherapy</i> , <b>2010</b> , 30, 776-86	5.8	52
61	Antimicrobial Treatment of Peritonitis Associated with Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , <b>1991</b> , 11, 252-260	2.8	47
60	Disposition of vancomycin during hemofiltration. <i>Clinical Pharmacology and Therapeutics</i> , <b>1986</b> , 40, 425-30	6.1	45
59	The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 56, 39-47	6.1	41
58	Impact of a pharmacist-physician collaborative care model on patient outcomes and health services utilization. <i>American Journal of Health-System Pharmacy</i> , <b>2018</b> , 75, 1039-1047	2.2	40

57	Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. <i>American Journal of Nephrology</i> , <b>1985</b> , 5, 35-9	4.6	39
56	Medication adherence challenges among patients experiencing homelessness in a behavioral health clinic. <i>Research in Social and Administrative Pharmacy</i> , <b>2015</b> , 11, e110-20	2.9	37
55	Medication knowledge and compliance among patients receiving long-term dialysis. <i>American Journal of Health-System Pharmacy</i> , <b>1995</b> , 52, 1895-900	2.2	36
54	Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 1639-44	5.9	35
53	Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. <i>Pharmacotherapy</i> , <b>2000</b> , 20, 635-43	5.8	34
52	Integration of collaborative medication therapy management in a safety net patient-centered medical home. <i>Journal of the American Pharmacists Association: JAPhA</i> , <b>2011</b> , 51, 167-72	1.7	33
51	Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. <i>Journal of Clinical Pharmacology</i> , <b>1998</b> , 38, 82-9	2.9	27
50	The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 56, 31-8	6.1	26
49	Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. <i>American Journal of Kidney Diseases</i> , <b>1996</b> , 28, S63-70	7.4	25
48	Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. <i>Clinical Pharmacology and Therapeutics</i> , <b>1985</b> , 38, 31-6	6.1	25
47	Gentamicin disposition in young and elderly patients with various degrees of renal function. <i>Journal of Clinical Pharmacology</i> , <b>1987</b> , 27, 216-20	2.9	24
46	Effects of liver disease on the disposition of the opioid antagonist nalmefene. <i>Clinical Pharmacology and Therapeutics</i> , <b>1997</b> , 61, 15-23	6.1	17
45	Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 1187-93	5.9	16
44	Disposition of minoxidil in patients with various degrees of renal function. <i>Journal of Clinical Pharmacology</i> , <b>1989</b> , 29, 798-802	2.9	16
43	Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. <i>Kidney International</i> , <b>2001</b> , 59, 295-303	9.9	15
42	Comparison of iothalamate clearance methods for measuring GFR. <i>Pharmacotherapy</i> , <b>1999</b> , 19, 943-50	5.8	14
41	Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain. <i>American Journal of Nephrology</i> , <b>1988</b> , 8, 90-5	4.6	14
40	An in vivo-in vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis. <i>Pharmacotherapy</i> , <b>2008</b> , 28, 977-83	5.8	13

39	Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. <i>Journal of Clinical Pharmacology</i> , <b>2006</b> , 46, 1299-307	2.9	13
38	The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. <i>Journal of Clinical Pharmacology</i> , <b>1996</b> , 36, 144-51	2.9	13
37	Gentamicin and tobramycin dosing guidelines: an evaluation. <i>Drug Intelligence &amp; Clinical Pharmacy</i> , <b>1983</b> , 17, 425-32		13
36	Status of Hemodialysis of Drugs in 2002. <i>Journal of Pharmacy Practice</i> , <b>2002</b> , 15, 405-418	1.3	12
35	Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 390-8	2.9	11
34	Pharmacotherapeutic consequences of recent advances in hemodialysis therapy. <i>Annals of Pharmacotherapy</i> , <b>1994</b> , 28, 512-4	2.9	9
33	Clinical pharmacokinetics 1990. <i>Clinical Pharmacokinetics</i> , <b>1990</b> , 18, 1-19	6.2	8
32	Health-care reform 2010: how will it impact you and your practice?. <i>Annals of Pharmacotherapy</i> , <b>2010</b> , 44, 1485-91	2.9	7
31	Disposition of guanadrel in subjects with normal and impaired renal function. <i>Journal of Clinical Pharmacology</i> , <b>1989</b> , 29, 128-32	2.9	7
30	Disposition of antipyrine and acetaminophen given alone and in combination to human subjects. <i>Pharmaceutical Research</i> , <b>1990</b> , 7, 204-7	4.5	7
29	The ADAPT online education program: A tool for practicing pharmacists delivering patient-centered care. <i>Journal of the American Pharmacists Association: JAPhA</i> , <b>2017</b> , 57, 601-607	1.7	6
28	Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 74, 555-68	6.1	6
27	Nephrology pharmaceutical care preceptorship: a programmatic and clinical outcomes assessment. <i>Annals of Pharmacotherapy</i> , <b>2000</b> , 34, 593-9	2.9	6
26	Effect of renal insufficiency on CYP activity.. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 155-155	6.1	6
25	Evaluation of three gentamicin serum assay techniques. <i>Therapeutic Drug Monitoring</i> , <b>1982</b> , 4, 195-200	3.2	6
24	Improving Health of At-Risk Rural Patients project: A collaborative care model. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 1760-1768	2.2	6
23	Pharmacokinetics of abecarnil in patients with renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 520-8	6.1	5
22	Protein binding of phenytoin, p-hydroxy phenytoin, and p-hydroxy phenytoin glucuronide. <i>Journal of Clinical Pharmacology</i> , <b>1986</b> , 26, 677-9	2.9	5

21	Development and Implementation of an Academic-Community Partnership to Enhance Care among Homeless Persons. <i>Innovations in Pharmacy</i> , <b>2011</b> , 2, 1-7	0.6	5
20	A Novel Education and Training Program to Enhance Student Advocacy. <i>American Journal of Pharmaceutical Education</i> , <b>2015</b> , 79, 95	2.5	4
19	Health care reform 2011: opportunities for pharmacists. <i>Annals of Pharmacotherapy</i> , <b>2012</b> , 46, S27-32	2.9	4
18	Clinical Pharmacokinetics of Anti-Infectives <b>1992</b> , 627-642		4
17	Population health and medicine: Policy and financial drivers. <i>American Journal of Health-System Pharmacy</i> , <b>2017</b> , 74, 1413-1421	2.2	3
16	Health Care Policy 2011: implications for pharmacists. <i>Annals of Pharmacotherapy</i> , <b>2011</b> , 45, 412-3	2.9	3
15	Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy. <i>ISRN Pharmacology</i> , <b>2012</b> , 2012, 782656		3
14	Effects of hemodialysis on plasma protein binding of bepridil. <i>Journal of Clinical Pharmacology</i> , <b>1995</b> , 35, 137-41	2.9	3
13	Heparin interferes with tobramycin serum concentration determinations by Emit. <i>Drug Intelligence &amp; Clinical Pharmacy</i> , <b>1984</b> , 18, 517-9		3
12	The relationship between medication-related problems and behavioural health condition among patients served by a health care for the homeless centre. <i>Journal of Pharmaceutical Health Services Research</i> , <b>2012</b> , 3, 173-178	1	2
11	Antifungal, Antitubercular, and Antiviral Agents. <i>Seminars in Dialysis</i> , <b>2007</b> , 1, 170-173	2.5	2
10	Doses of histamine-2-receptor antagonists should be reduced in patients with low glomerular filtration rate. <i>Nature Clinical Practice Nephrology</i> , <b>2006</b> , 2, 298-9		1
9	Life on Capitol Hill: A pharmacist's perspective. <i>American Journal of Health-System Pharmacy</i> , <b>2006</b> , 63, 725-30	2.2	0
8	Principles of Drug Therapy in Patients with Reduced Kidney Function <b>2014</b> , 337-345		
7	Executive summary: The Virginia Commonwealth University pharmacy practice transformation conference. <i>Annals of Pharmacotherapy</i> , <b>2012</b> , 46, S1-11	2.9	
6	Antibiotics: Antianaerobic Agents, Quinolones, and Tetracyclines. <i>Seminars in Dialysis</i> , <b>2007</b> , 1, 220-223	2.5	
5	Antibiotics: Vancomycin. <i>Seminars in Dialysis</i> , <b>2007</b> , 2, 54-55	2.5	
4	Nephropathy as a hazard of analgesic abuse. <i>American Journal of Health-System Pharmacy</i> , <b>1981</b> , 38, 1536-1540		

- 3 Documenting the influence of clinical pharmacists. *American Journal of Health-System Pharmacy*, **1982**, 39, 481-482 2.2
- 2 Effect of quinidine on serum digoxin concentrations. *American Journal of Health-System Pharmacy*, **1979**, 36, 968-971 2.2
- 1 Principles of Drug Therapy in Patients with Reduced Kidney Function **2009**, 322-329